Intec Pharma Ltd (NASDAQ:NTEC) has been assigned a $10.00 target price by Roth Capital in a research report issued to clients and investors on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock. Roth Capital’s price objective indicates a potential upside of 85.19% from the company’s previous close.

Several other research firms also recently commented on NTEC. Zacks Investment Research downgraded shares of Intec Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 24th. ValuEngine cut shares of Intec Pharma from a “hold” rating to a “sell” rating in a research report on Friday, June 9th. Finally, Maxim Group set a $9.00 price objective on shares of Intec Pharma and gave the stock a “buy” rating in a research report on Wednesday, May 24th.

Shares of Intec Pharma (NTEC) traded down 0.92% during mid-day trading on Thursday, hitting $5.40. The stock had a trading volume of 2,246 shares. Intec Pharma has a 12 month low of $4.20 and a 12 month high of $6.36. The stock’s 50-day moving average is $5.49 and its 200 day moving average is $5.25. The firm’s market cap is $74.18 million.

ILLEGAL ACTIVITY WARNING: “Intec Pharma Ltd (NTEC) Given a $10.00 Price Target at Roth Capital” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Receive News & Ratings for Intec Pharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd and related companies with's FREE daily email newsletter.